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parison was non-randomised no differences were
found between groups to explain away the finding sta-
tistically. Some reassurance comes from stroke preven-
tion with ramipril with a nearly identical reduction
(4/3 mm Hg) in blood pressure in the heart outcomes
prevention evaluation (HOPE) study (similarly irre-
spective of starting blood pressure).9 HOPE, however,
included only 1013 patients with a prior cerebrovascu-
lar event—too few for confident conclusions regarding
the efficacy of monotherapy with ACE inhibitors in
this population. Indapamide, on the other hand, has
evidence of benefit as monotherapy from PATS. Over-
all combined ACE inhibitor and diuretic treatment has
the best supporting evidence.
These developments expand secondary preventive
options greatly: as many as 84% of patients with
transient ischaemic attack and stroke are now prescribed
antihypertensive drugs, statins, or non-aspirin antiplate-
let agents in addition to any pre-existing medication.w4
However, the probability that lifelong multidrug
treatment is recommended places added responsibility
on clinicians to improve diagnostic accuracy since only
about half of those referred as transient ischaemic attack
have actually had one.w5 Since typically 30% of patients
referred to special clinics for transient ischaemic attacks
have other neurological diagnoses, training in the
United Kingdom—where few neurologists participate in
stroke services—must take this into account. While the
prospect of routine polypharmacy is daunting, both for
younger patients unaccustomed to illness and for elderly
patients with multiple comorbidities who may be
vulnerable to drug interactions and symptomatic hypo-
tension, the consequence of failing to translate the
results of this trial into practice will be avoidable
disabling or fatal strokes.
That transient ischaemic attack and minor stroke
are medical emergencies is reinforced by new commu-
nity based data that confirm a far higher risk of subse-
quent stroke than has conventionally been appreci-
ated. The seven day risk of stroke is between 8-12%:
other studies have found risk to be as high as 20% in
some patient groups.10 11 Whether the benefits of
secondary preventative pharmacotherapy extend to
this very early period is unknown, but will be tested in
ongoing trials of combination antiplatelet therapy (fast
assessment of stroke and transient ischaemic attack to
prevent early recurrence—FASTER and prevention
regimen for effectively avoiding second strokes—
PRoFESS), statins (FASTER), and blood pressure
lowering (PRoFESS). If these trials find benefits similar
to those from PROGRESS and HPS, then the time will
have arrived to abandon the still prevalent tendency to
dismiss events as “just a TIA” and to advance into an
era of acute cerebrovascular syndromes meriting treat-
ment as aggressive as cardiologists currently employ
for the coronary equivalent.
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Compulsory screening of immigrants for
tuberculosis and HIV
Is not based on adequate evidence, and has practical and ethical problems
Increased movements of peoples are stressing pub-lic health responses to threats from communicablediseases internationally. This year several bodies in
the United Kingdom, including the Conservative party,
have called for compulsory screening of immigrant
populations for tuberculosis and HIV in order to sup-
port national efforts to control these communicable
diseases. Given that concerns about asylum policy are
consistently high on the political agenda, and that the
media have recently taken to conflating anti-immigrant
sentiments with public health threats through commu-
nicable diseases,1 the government may be considering
compulsory screening of immigrants for some
infectious diseases. But is there a rational public health
argument that is grounded in evidence for compulsory
screening of immigrants?
For tuberculosis and HIV the purpose of screening
should be twofold—to identify cases early such that indi-
viduals can be offered treatment and care, and so to
inhibit further transmission (through treatment, behav-
iour change, or isolation) to protect public health.
For tuberculosis the notion that screening immi-
grants detects those with the disease and therefore
benefits public health is not straightforward. Although
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the increase in rates of tuberculosis in England and
Wales over the past decade is clearly associated with
immigrants, this does not translate into a cogent argu-
ment in favour of screening immigrants, never mind
compulsory screening.2
Most active tubercular disease seems to develop
after immigration.3 Clearly, those individuals in whom
tuberculosis is identified early can benefit from
treatment, but little evidence exists to show that early
detection of tuberculosis in foreign born individuals
conveys appreciable public health benefit to those
born in the host country. This is not to say that people
who live in close proximity might not be at greater risk,
but that if the health of immigrant populations and
those among whom recently arrived immigrants reside
is the cause for concern then perhaps this should be an
explicit rationale.4–6
Although current programmes of screening for
active disease focus on asylum seekers, in whom preva-
lence rates are relatively high, very few active cases and
fewer infectious cases are actually identified.7 More-
over, little correlation exists between the prevalence of
disease in countries of origin and prevalence of active
disease in those screened.
Given that immigrant groups other than those seek-
ing asylum (including those who are undocumented,
who are students, and who are seeking employment)
have not traditionally been the focus of attention, a
screening programme that attempts to encompass such
diverse groups is likely to face substantial practical issues
whether such a system is pre-entry, post-entry, or a com-
bination of the two. Moreover, such a programme if
implemented would be based on evidence with shallow
foundations. An important practical problem in screen-
ing for active tuberculosis is that the tool used,
principally the chest radiograph, results in large
numbers of false positive results, incurring substantial
human and capital cost.8
Before supporting public health interventions
through coercive measures policy makers need to
show the effectiveness of a proposed intervention.9
And any benefits that might be accrued through the
use of compulsion are certainly not grounded in
evidence. Indeed what little evidence exists suggests
that few migrants currently identified through screen-
ing abscond and that the introduction of compulsory
measures may mean that some patients may delay
seeking care and pose a greater public health threat.10
For HIV the issues are somewhat different. Unlike
for tuberculosis, the tools to detect HIV infection are
highly sensitive and specific, and the potential benefits
from screening to the individual and public health may
on the surface seem more straightforward.
Data from the Health Protection Agency show that
immigrant associated HIV is increasing and that most
is acquired heterosexually abroad before coming to
medical attention in the United Kingdom.Moreover, of
the cumulative total of 2046 HIV infected individuals
notified who are thought to have acquired HIV in the
United Kingdom, 944 are thought to have become
infected by someone originating from outside Europe,
whereas in 542 (or a third of those in whom details
were known) exposure in the United Kingdom
originated from a partner from within Europe.
Thus, much HIV infection is acquired abroad, and
there is evidence of heterosexual transmission in the
United Kingdom, which is linked to immigrant-
associated HIV. Clearly there are (or should be)
individual benefits to be gained from knowing one’s
HIV status in terms of treatment and care. And there are
public health benefits to be gained if immigrants
infected with HIV become aware of their status and as a
consequence do not transmit the virus. So, given these
benefits, should compulsory screening of immigrants be
part of public health policy in the United Kingdom?
Several important practical and ethical questions
regarding screening of immigrants for HIV need to be
looked at, and many of them are unresolved.
From a practical perspective, would such a policy
focus on all migrants, immigrants from high preva-
lence countries, asylum seekers, or some as yet
unspecified population? Most asylum seekers are HIV
negative, and most immigrants who are HIV positive
are not asylum seekers. If screening is applied to popu-
lations from countries that have prevalence rates above
a certain threshold then immigrants from areas that
have a low prevalence may not be detected.What about
populations which are able to move freely? The free
movements of people from within the European
Union and from countries within next year’s expanded
European Union may not be subjected to screening.
Yet the future eastern border of the European Union
will be with countries that have the most rapidly
escalating epidemics of HIV in the world, notably Rus-
sia, Belarus, and Ukraine, and security at this new east-
ern border has been criticised recently. A further
question is, how would such a policy address migrants
who remain undocumented? Would a fear of the con-
sequences of a potentially positive result mean the
undocumented population challenged public health to
a greater degree? Given that individuals are likely to
travel back to their country of origin on occasion,
should they be tested after each visit?
If determination of a positive status excludes an indi-
vidual from entry (as has been proposed) then might
such a screening policy have the perverse effect of creat-
ing incentives to avoid legal routes of entry and pursue
illegal routes or falsify supporting documentation? How
would this be countered? The assumption seems to be
that people infected with HIV pose a public health
threat simply by virtue of being infected. But HIV is
unlike tuberculosis. Where tuberculosis can be acquired
passively, simply through breathing the same air,
transmission of HIV requires an activity such as sex or
injecting. Consequently it is those who are HIV infected
and participate in such activities who pose a public
health challenge. Do people change their behaviour
when they know they are infected, and is this behaviour
change likely to occur and be sustained if testing is con-
ducted coercively? The public health benefits gained
through awareness of one’s status may be lost through
the manner in which that knowledge is gained.
Obvious ethical issues include the possibility of dis-
crimination, notions of confidentiality (often lost when
compulsion is involved), the role of clinicians as both
patient advocates and protectors of public health, and
stigma.
The United Kingdom has an enviable reputation in
international public health. In recent decades this has
rested in part on a humane public health policy
response to HIV—where a position was taken early in
the pandemic to protect human rights and provide
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care and succour to those in society most marginalised
and stigmatised. This approach also happened to be
rational, coherent, and effective. It would be a shame if
this reputation was tarnished through an ill considered
conflation of immigration control and communicable
disease control.
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Portable echocardiography
Is essential for the management of acutely ill patients
As the number of patients presenting with acuteconditions to emergency and intensive careunits continues to grow traditional ward based
models of care may no longer be adequate. Reorgani-
sation of critical care services is a government priority,
encapsulating the paradigm that rapid assessment and
treatment of modifiable life threatening conditions is
required regardless of the location of the patient.1
Failures of all organ systems are potentially life threat-
ening, but arguably the most catastrophic is failure of
the cardiovascular system. Quick deployment of
diagnostic aids to the bedside and identifying patients
at risk therefore assume great importance.
Advances in microprocessor technology have
permitted cardiac ultrasound to evolve from the crude
1953 oscilloscopes of Edler and Hertz through power-
ful but essentially immobile echocardiographs to port-
able battery powered devices that even incorporate the
capacity for Doppler interrogation. This portability
brings with it the opportunity for widespread use at the
bedside with the potential to afford unprecedented
benefit in immediate diagnosis. Such developments
pose two major questions. What are the clinical
applications of these portable machines, and what
training should potential operators receive?
Clinical studies show that portable echocardio-
graphy can be used to initiate and modify treatment,
particularly in patients with cardiac conditions. Investi-
gators have shown that basic assessment of ventricular
function, measurement of the dimensions of the
ventricular chamber, and identification of structural
lesions including valvular regurgitation or stenosis and
pericardial effusions is possible in all patients except
those least amenable to echocardiography. The
sensitivity of portable echocardiography for the detec-
tion of cardiac abnormalities is higher than that of
clinical examination and reaches 70-90% compared
with conventional echocardiography.2–5 Although port-
able echocardiography is not without notable
limitations—particularly with relation to spectral
Doppler, harmonic imaging, probe footprint size, reso-
lution, and storage facilities—the procedure
nevertheless seems adequate in trained hands, for lim-
ited studies where the context of the study and the
clinical questions posed are clearly predefined.
As a result of limited studies several leading echocar-
diologists have concluded that novice non-cardiologists,
with as little as three hours of training, are capable of
making relatively reliable assessments by portable echo-
cardiography of ventricular function and other life
threatening conditions, including pericardial effusion.6–9
In contrast to this general success of portable
echocardiography, a study based in intensive care units
indicated that up to 31% of important findings were
missed, probably due to suboptimal imaging.10 Although
the technology has advanced since this study, on the
basis of our own experience we remain cautious. We
agree with current recommendations that portable
echocardiography should not be used to influence the
management of patients by inexperienced clinicians.11
Advocates of portable echocardiography have pro-
posed that this technology should be incorporated into
medical students’ curriculums and ultimately dissemi-
nated generally. However, in the absence of definitive
evidence from desperately needed field studies a prag-
matic approach should be adopted, balancing the lim-
ited training needs of portable echocardiography to be
performed acutely at the point of care with the
comprehensive approach advocated for cardiologists.11
Although most doctors have a fairly circumscribed
knowledge of electrocardiography and radiology, they
use these tools to address specific triage questions to
guide urgent and powerful treatments (for example,
thrombolysis for acute myocardial infarction) but
ultimately defer to specialists for ongoing management.
Training in portable echocardiography should not be
aimed to produce clinicians capable of performing
complete studies any more than we train doctors to per-
form or report computed tomography scans. Instead, by
restricting operators to a minimum familiarity with
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